Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Study to Evaluate the Safety and Efficacy of BAT1308 Combined with Platinum-Based Chemotherapy ± Bevacizumab As First-Line Therapy for PD-L1-Positive (CPS ≥ 1) Persistent, Recurrent or Metastatic Cervical Cancer

NCT06123884 is registered in ClinicalTrials.gov with Bio-Thera Solutions as lead sponsor.

NCT NCT06123884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06123884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Study to Evaluate the Safety and Efficacy of BAT1308 Combined with Platinum-Based Chemotherapy ± Bevacizumab As First-Line Therapy for PD-L1-Positive (CPS ≥ 1) Persistent, Recurrent or Metastatic Cervical Cancer
Lead sponsor
Bio-Thera Solutions
Phase
Phase 2/3
Overall status
Recruiting
Start date
December 13, 2023
Completion date
January 31, 2027
Enrollment
526 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer